Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice

被引：0

作者：

Hongbo Wang

Frederick Bauzon

Peng Ji

Xiaoliang Xu

Daqian Sun

Joseph Locker

Rani S Sellers

Keiko Nakayama

Keiich I Nakayama

David Cobrinik

Liang Zhu

机构：

[1] The Albert Einstein Comprehensive Cancer Center and Liver Research Center,Department of Developmental and Molecular Biology and Medicine

[2] Albert Einstein College of Medicine,Department of Pathology

[3] Dyson Vision Research Institute,Department of Functional Genomics, Division of Developmental Genetics

[4] Weill-Cornell Medical College,Department of Molecular and Cellular Biology

[5] The Albert Einstein Comprehensive Cancer Center and Liver Research Center,undefined

[6] Albert Einstein College of Medicine,undefined

[7] Tohoku University Graduate School of Medicine,undefined

[8] Medical Institute of Bioregulation,undefined

[9] Kyushu University,undefined

[10] Present addresses: Whitehead Institute for Biomedical Research,undefined

[11] Cambridge,undefined

[12] Massachusetts,undefined

[13] USA (P.J.); Peptide Binding Laboratory,undefined

[14] The Salk Institute,undefined

[15] La Jolla,undefined

[16] California,undefined

[17] USA (H.W.); Departments of Pathology (X.X.) and Pediatrics (D.C.),undefined

[18] Memorial Sloan-Kettering Cancer Center,undefined

[19] New York,undefined

[20] New York,undefined

[21] USA.,undefined

来源：

Nature Genetics | 2010年 / 42卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Liang Zhu and colleagues report that inactivation of Skp2, a target of the pRb tumor suppressor, completely prevented tumorigenesis in tumor-prone mice with loss of one Rb1 allele. This work nominates Skp2 as a drug target to combat Rb1-deficient tumors.

引用

页码：83 / 88

页数：5

共 50 条

[1] Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice
Wang, Hongbo
Bauzon, Frederick
Ji, Peng
Xu, Xiaoliang
Sun, Daqian
Locker, Joseph
Sellers, Rani S.
Nakayama, Keiko
Nakayama, Keiich I.
Cobrinik, David
Zhu, Liang
NATURE GENETICS, 2010, 42 (01) : 83 - U105
[2] Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition
Gupta, Pranav
Zhao, Hongling
Hoang, Bang
Schwartz, Edward L.
BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 969 - 975
[3] Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition
Pranav Gupta
Hongling Zhao
Bang Hoang
Edward L. Schwartz
British Journal of Cancer, 2022, 127 : 969 - 975
[4] Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity
Zhonglei Lu
Frederick Bauzon
Hao Fu
Jinhua Cui
Hongling Zhao
Keiko Nakayama
Keiich I. Nakayama
Liang Zhu
Nature Communications, 5
[5] Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity
Lu, Zhonglei
Bauzon, Frederick
Fu, Hao
Cui, Jinhua
Zhao, Hongling
Nakayama, Keiko
Nakayama, Keiich I.
Zhu, Liang
NATURE COMMUNICATIONS, 2014, 5
[6] SKP2 Activation by Thyroid Hormone Receptor β2 Bypasses Rb-Dependent Proliferation in Rb-Deficient Cells
Xu, Xiaoliang L.
Li, Zhengke
Liu, Aihong
Fan, Xianqun
Hu, Dan-ning
Qi, Dong-Lai
Chitty, David W.
Jia, Renbing
Qui, Jianping
Wang, Justin Q.
Sharaf, Jake
Zou, Jun
Weiss, Rebecca
Huang, Hongyan
Joseph, Walter J.
Ng, Lily
Rosen, Richard
Shen, Binghui
Reid, Mark W.
Forrest, Douglas
Abramson, David H.
Singer, Samuel
Cobrinik, David
Jhanwar, Suresh C.
CANCER RESEARCH, 2017, 77 (24) : 6838 - 6850
[7] Genetic and pharmacologic inhibition of Skp2, an E3 ubiquitin ligase and RB1-target, has antitumor activity in RB1-deficient human and mouse small cell lung cancer (SCLC)
Zhao, Hongling
Sukrithan, Vineeth
Iqbal, Niloy
Nicholas, Cari
Xue, Yingjiao
Locker, Joseph
Zou, Juntao
Zhu, Liang
Schwartz, Edward L.
CANCER RESEARCH, 2020, 80 (16)
[8] Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival
Li, George Z.
Okada, Tomoyo
Kim, Young-Mi
Agaram, Narasimhan P.
Sanchez-Vega, Francisco
Shen, Yawei
Tsubokawa, Norifumi
Rios, Jordan
Martin, Axel S.
Dickson, Mark A.
Qin, Li-Xuan
Socci, Nicholas D.
Singer, Samuel
CANCER RESEARCH, 2020, 80 (12) : 2461 - 2471
[9] Evaluating Cks1-Skp2 interface as an effective therapeutic target for RB1-deficient metastatic castration-resistant prostate cancer (mCRPC).
Xue, Yingjiao
Zhu, Liang
Zhao, Hongling
Schwartz, Edward L.
CANCER RESEARCH, 2021, 81 (13)
[10] Rb-deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma have Oncogene Addiction to Skp2 and Show High Sensitivity to Skp2 Inhibitors
Li, G.
Xu, X.
Agaram, N.
Socci, N.
Singer, S.
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S47 - S47

← 1 2 3 4 5 →